News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sumitomo Pharmaceuticals Co. Ltd., Novo Nordisk (NVO) Conclude Licensing Agreement For Repaglinide


10/19/2005 5:11:24 PM

Sumitomo Pharmaceuticals, Co., Ltd. announces that it has concluded a license agreement with Novo Nordisk A/S (Denmark) for the anti-diabetic agent, Repaglinide (generic name) which will enable Sumitomo Pharmaceuticals to develop and market the drug in Japan.

Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES